Browse drugs

…ansen JS, Larsen FO, Theile S, Hasselby JP, Willemoe GL, et al. Nivolumab with or without ipilimumab combined with stereotactic body radi…

…-1 monotherapy, whereas anti-RPLP2 was associated with irAEs in ipilimumab/nivolumab combination therapy. For ir-colitis, 38 autoantibodie…

… with an objective response.Conclusions mKRAS-VAX combined with ipilimumab and nivolumab was well-tolerated and resulted in clinical respo…

…nter. Patients received either nivolumab + ipilimumab (n=21) or pembrolizumab monotherapy (n=31). Radiological responses were assessed using …

…e clinical trial.Methods This is an open-label phase 2 trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg in…

…rolled in a first-line phase II trial of the anti-PD-1 antibody nivolumab.13 Together, these data suggest then an immunologically enriche…

…t saving of €11,000 per patient when using Nivolumab instead of Pembrolizumab, with equivalent efficacy. This finding supports a review of pr…

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…ase describes severe immune-mediated toxicity after one dose of ipilimumab (1 mg/kg) and nivolumab (3 mg/kg) in a stage IV patient who dev…

…CD16+/CD137+) at 1 week after the first infusion, regardless of W0180 dose (online supplemental figure S7).Of the pro-inflammatory cy…

…-mediated mechanism, most likely as an immune-related effect of ipilimumab and nivolumab.…

… while reducing binding to inhibitory FcγRIIb. In mouse models, ROSE12 monotherapy significantly inhibited tumor growth in both conven…